参考文献/References:
[1] 范亚光,周清华,乔友林,等.中国肺癌低剂量CT筛查指南(2023年版)[J].中国肺癌杂志,2023,26(1):1-9.
[2] 肖凌,王洋,钱建新,等.生脉饮合沙参麦冬汤联合西药治疗晚期非小细胞肺癌疗效研究[J].陕西中医,2021,42(12):1696-1699.
[3] BASSE C,SWALDUZ A,MC LEER A,et al.NSCLC and new oncogenic mutations:Diagnosis and perspectives[J].Rev Mal Respir,2021,38(5):477-488.
[4] GILLESPIE C S,MUSTAFA M A,RICHARDSON G E,et al.Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC:A systematic review and meta-analysis[J].J Thorac Oncol,2023,18(12):1703-1713.
[5] ZENG Y,YU D,TIAN W,et al.Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer[J].Curr Opin Oncol,2022,34(1):54-65.
[6] 陈润芝,雷昊,徐慧婷,等.阿帕替尼联合EGFR-TKI一线治疗EGFR敏感突变的晚期非鳞非小细胞肺癌的疗效和安全性分析[J].临床肿瘤学杂志,2021,26(12):1131-1135.
[7] SIEGEL R L,MILLER K D,WAGLE N S,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[8] 李邦胜,杨政鸿,赵应鼎,等.多原发肺癌诊疗策略的最新进展[J].中国肺癌杂志,2023,26(11):863-873.
[9] SVATON M.Targeted therapy of non-small cell lung cancer[J].Klin Onkol,2021,4(S1):48-52.
[10] ATTILI I,PASSARO A,PISAPIA P,et al.Uncommon EGFR compound mutations in non-small cell lung cancer(NSCLC):A systematic review of available evidence[J].Curr Oncol,2022,29(1):255-266.
[11] 荆冠军,赵一鉴.阿帕替尼治疗晚期肺癌对患者血清肿瘤标志物的影响研究[J].陕西医学杂志,2020,49(10):1351-1355.
[12] 王守正,邢镨元,王燕,等.EGFR突变晚期非小细胞肺癌患者一线阿法替尼治疗的颅内疗效及其影响因素分析[J].癌症,2023,42(7):371-383.
[13] DI NOIA V,D'AVENI A,D'ARGENTO E,et al.Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer:Novel targeted agents and combination strategies[J].ESMO Open,2021,6(6):100280.
[14] SOO R A,HAN J Y,DAFNI U,et al.A randomised phase Ⅱstudy of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations:The European Thoracic Oncology Platform(ETOP 10-16)BOOSTER trial[J].Ann Oncol,2022,33(2):181-192.
[15] 孟璠璐,刘瑜,程轩,等.小细胞肺癌药物治疗研究进展[J].陕西医学杂志,2022,51(10):1313-1317.
[16] POPAT S,AHN M J,EKMAN S,et al.Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases:Current evidence and future perspectives on therapeutic strategies[J].Target Oncol,2023,18(1):9-24.
[17] PAPADIMITRAKOPOULOU V A,MOK T S,HAN J Y,et al.Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor:AURA3 overall survival analysis[J].Ann Oncol,2020,31(11):1536-1544.
[18] VAID A K,GUPTA A,MOMI G.Overall survival in stage Ⅳ EGFR mutationpositive NSCLC:Comparing first,second and thirdgeneration EGFRTKIs(review)[J].Int J Oncol,2021,58(2):171-184.
[19] HUI C,QU V,WANG J Y,et al.Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer[J].J Neurooncol,2022,160(1):233-240.
[20] WANG N,ZHANG Y,MI Y,et al.Osimertinib for EGFR-mutant lung cancer with central nervous system metastases:A meta-analysis and systematic review[J].Ann Palliat Med,2020,9(5):3038-3047.
[21] COLCLOUGH N,CHEN K,JOHNSTRÖM P,et al.Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs[J].Clin Cancer Res,2021,27(1):189-201.
[22] ETTINGER D S,WOOD D E,AISNER D L,et al.NCCN guidelines insights:Non-small cell lung cancer,version 2.2021[J].J Natl Compr Canc Netw,2021,19(3):254-266.
[23] 王翠翠,耿利民.血清癌胚抗原对表皮生长因子受体基因突变非小细胞肺癌分子靶向治疗疗效的预测价值[J].陕西医学杂志,2020,49(7):834-837.
[24] ZHAO Y,GUO S,DENG J,et al.VEGF/VEGFR-Targeted therapy and immunotherapy in non-small cell lung cancer:Targeting the tumor microenvironment[J].Int J Biol Sci,2022,18(9):3845-3858.
[25] CHO B C,FELIP E,HAYASHI H,et al.MARIPOSA:Phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer[J].Future Oncol,2022,18(6):639-647.